Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Trump expected to pick White House aide to lead FDA

19 August 2026 · By · Wire by Fusion42

Published

19 August 2026

Topic

regulatory

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at washingtonpost.com →

◆ Verified

Fusion42 · 19 August 2026 · Fusion42 review

President Donald Trump is expected to appoint Heidi Overton, a White House Domestic Policy Council aide, as the new commissioner of the Food and Drug Administration, replacing Marty Makary who resigned in May amid agency turmoil.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

FDA leadership has shifted to someone deeply connected to White House policy, which means you should prepare for quicker regulatory moves aligned with administration priorities and potential policy shifts in drug and health products approval.

◆ Coverage

1 source · 19 Aug 2026

◆ Related on Wire

◆ Topics

Healthfdaleadership-changeus-health-policyregulatory-shift